News
About the PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
Download Now: New Slide Deck Programme
Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »
ACC.20 with the World Congress of Cardiology
Virtual Meeting 28-30 March
Polygenic risk, LDL and SBP
Inclisiran: Data for >3,600 patients
Evinacumab: Nearly halves LDL-C in HoFH
ODYSSEY HoFH: Alirocumab shows benefit
AHA Scientific Sessions 2019
16-18 November, Philadelphia, USA
ORION-9: durable and potent LDL-C lowering in HeFH patients on twice yearly dosing
FOURIER: effects of evolocumab on cognition and following MI
Hot Topics
12th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum
Remnant lipoproteins and impact of PCSK9 inhibition
Professor Chris Packard (Institute of Cardiovascular and Medical Sciences, Glasgow University, UK) discusses how PCSK9 inhibition might affect remnant particles.
What’s new in high-risk patients?
Professor Francois Mach (Geneva University Hospital, Switzerland)
From the Editors
Looking beyond LDL: PCSK9 inhibition and remnants
Professor Chris Packard (Institute of Cardiovascular and Medical Sciences, Glasgow University, UK) discusses how PCSK9 inhibition might affect remnant particles.
Other related reports:
Did someone say “Beyond LDL-cholesterol”?
Read the report
New EAS Consensus Panel statement: an Opus for LDL-driven mechanisms in atherosclerosis
Read the report
Latest Views
Meet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie
Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
